Evidence map›Paper›PMID 36326252›Full record

ArticlemBio2022

Transcriptional Biomarkers of Differentially Detectable Mycobacterium tuberculosis in Patient Sputum.

Kayvan Zainabadi, Kohta Saito, Saurabh Mishra, Kathleen Frances Walsh, Laurent Daniel Mathurin, Stalz Charles Vilbrun, Oksana Ocheretina, Jean William Pape, Daniel W Fitzgerald, Carl F Nathan and 1 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Differentially culturableJournal of medical microbiology · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Eradication of Drug-TolerantMicroorganisms · 2023
    Review
  6. The performance of tongue swabs for detection of pulmonary tuberculosis.Frontiers in cellular and infection microbiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Kayvan ZainabadiCenter for Global Health, Weill Cornell Medicine, New York, New York, USA.ORCID 0000-0003-3134-1783
Kohta SaitoDepartment of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA.
Saurabh MishraDepartment of Microbiology & Immunology, Weill Cornell Medicine, New York, New York, USA.
Kathleen Frances WalshCenter for Global Health, Weill Cornell Medicine, New York, New York, USA.ORCID 0000-0002-9001-3918
Laurent Daniel MathurinLes Centres GHESKIO, Port-au-Prince, Haiti.
Stalz Charles VilbrunLes Centres GHESKIO, Port-au-Prince, Haiti.
Oksana OcheretinaCenter for Global Health, Weill Cornell Medicine, New York, New York, USA.
Jean William PapeCenter for Global Health, Weill Cornell Medicine, New York, New York, USA.
Daniel W FitzgeraldCenter for Global Health, Weill Cornell Medicine, New York, New York, USA.
Carl F NathanDepartment of Microbiology & Immunology, Weill Cornell Medicine, New York, New York, USA.ORCID 0000-0002-7744-8896
Myung Hee LeeCenter for Global Health, Weill Cornell Medicine, New York, New York, USA.
Cornell University · USGheskio Centers · HT

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Viable but Nonculturable MtbU19AI111143 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI FITZGERALD, DANIEL W, GLICKMAN, MICHAEL S · 2014 to 2020
$48.6M
Pharmacology & ImmunoPathology (PIP) CoreU19AI162568 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI EHRT, SABINE · 2021 to 2025
$13.0M
Vanderbilt-Emory-Cornell-Duke Global Health Fellowship Consortium-Expanding Diversity for Global Equity (EDGE)D43TW009337 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALIYU, MUKTAR HASSAN, HEIMBURGER, DOUGLAS CORBETT · 2017 to 2021
$6.3M
Global Health Research Training in HIV and TuberculosisK24AI098627 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI FITZGERALD, DANIEL W · 2012 to 2022
$1.8M
Identifying the Molecular Target of Two Novel Compounds Active Against Non-replicating Mycobacterium tuberculosis and Delineating the Role of the Putative Target, InhA, in Non-replicating StatesK08AI139360 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SAITO, KOHTA · 2019 to 2023
$860k
FIC NIH HHS D43 TW009337NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384NIAID NIH HHS K08 AI139360NIAID NIH HHS K24 AI098627NIAID NIH HHS U19 AI111143NIAID NIH HHS U19 AI162568
6 · The paper itself

Abstract

Certain populations of Mycobacterium tuberculosis go undetected by standard diagnostics but can be enumerated using limiting dilution assays. These differentially detectable M. tuberculosis (DD M. tuberculosis) populations may have relevance for persistence due to their drug tolerance. It is unclear how well DD M. tuberculosis from patients is modeled by a recently developed

Indexed as

Mycobacterium tuberculosisTuberculosisAntitubercular AgentsHumansRifampinRNA, Ribosomal, 16SSensitivity and SpecificitySputumAntitubercular AgentsRifampinRNA, Ribosomal, 16Sclinical methodsdiagnosticsdifferentially detectable bacteriamolecular methodsmultidrug resistanceMycobacterium tuberculosispersistenceviable but nonculturable

Identifiers

PMID36326252
PMCPMC9765512
OpenAlexW4308058527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.